Public Health Implications of Gene Editing
Gene editing, particularly with the advent of CRISPR-Cas9 and other advanced technologies, holds transformative potential for public health. It offers unprecedented opportunities to prevent and treat a wide array of genetic disorders, infectious diseases, and even some forms of cancer. However, these advancements also raise significant ethical, social, and regulatory challenges. Gene editing can potentially cure genetic disorders such as cystic fibrosis, sickle cell anemia, and muscular dystrophy by correcting mutations at the DNA level. Gene drives can be used to reduce or eliminate populations of disease-carrying insects, such as mosquitoes, thereby reducing the incidence of diseases like malaria and dengue fever. Gene editing can enable the development of personalized medical treatments based on an individual’s genetic makeup, improving efficacy and reducing adverse effects. Editing the germline (changes that are heritable) raises profound ethical questions about the potential for unintended consequences and the long-term impact on human evolution. Gene editing holds immense promise for improving public health by providing new ways to prevent and treat diseases. However, realizing these benefits requires careful consideration of ethical, social, and regulatory challenges
Related Conference of Public Health Implications of Gene Editing
16th International Conference on Human Genetics and Genetic Diseases
19th International Conference on Genomics & Pharmacogenomics
19th World Congress on Advances in Stem Cell Research and Regenerative Medicine
Public Health Implications of Gene Editing Conference Speakers
Recommended Sessions
- Bioinformatics in Cell and Gene Therapy
- CAR-T Cell Therapy: Current Status and Future Directions
- Cell Therapy for Cardiovascular Diseases
- Cell-Based Therapies for Neurological Disorders
- Cellular Reprogramming and Induced Pluripotent Stem Cells
- Clinical Trials in Cell and Gene Therapy
- Drug Delivery Strategies for Gene Therapies
- Ethical Considerations in Genome Editing
- Gene Editing Technologies: CRISPR and Beyond
- Gene Therapy for Ophthalmic Diseases
- Immunotherapy in Cancer Treatment
- Manufacturing Challenges and Solutions in Cell and Gene Therapy
- Patient Advocacy and Engagement in Clinical Trials
- Public Health Implications of Gene Editing
- Recent Advances in Stem Cell Research
- Regenerative Medicine and Tissue Engineering
- Regulatory Landscape for Cell and Gene Therapies
- The Evolution of Cell and Gene Therapy
- Vector Development for Gene Therapy
Related Journals
Are you interested in
- 3D Bioprinting, Organ Fabrication & Bioartificial Tissues - Stem Cell 2026 (Netherlands)
- Advanced Gene Therapeutics - Cell Signaling 2026 (France)
- Aging Biology, Longevity Science & Cellular Rejuvenation - Stem Cell 2026 (Netherlands)
- Animal Genetics - Genome 2026 (Singapore)
- Artificial Intelligence and Computational Biology in Regenerative Medicine - Stemgen 2026 (Japan)
- Bioengineering Therapeutics - Cell Signaling 2026 (France)
- Bioinformatics and Computational Biology - Genome 2026 (Singapore)
- Bioinformatics, AI Models & Predictive Regeneration - Stem Cell 2026 (Netherlands)
- Biomarkers and Microarrays - Genome 2026 (Singapore)
- Biomaterials and Nanotechnology in Regenerative Medicine - Stemgen 2026 (Japan)
- Cancer Genomics - Genome 2026 (Singapore)
- Cancer Stem Cells & Targeted Therapeutics - Stem Cell 2026 (Netherlands)
- Cancer Stem Cells and Oncology - Stemgen 2026 (Japan)
- Cardiac, Vascular & Musculoskeletal Regeneration - Stem Cell 2026 (Netherlands)
- Cardiovascular Regeneration - Stemgen 2026 (Japan)
- Cell Biology - Cell Signaling 2026 (France)
- Cell Culture and Bioprocessing - Cell Signaling 2026 (France)
- Cell Cycle/Proliferation - Cell Signaling 2026 (France)
- Cell Death and Viability - Cell Signaling 2026 (France)
- Cell Science and Stem Cell Research - Cell Signaling 2026 (France)
- Cellular Signaling - Cell Signaling 2026 (France)
- Cellular Therapies - Cell Signaling 2026 (France)
- Clinical genomics - Genome 2026 (Singapore)
- Clinical Translation of Stem Cell Therapies - Stem Cell 2026 (Netherlands)
- Clinical Trials and Research in Stem Cell in Cancer Therapy - Cell Signaling 2026 (France)
- Clinical Trials and Translational Stem Cell Research - Stemgen 2026 (Japan)
- Commercialization, Biobanking & Industry Innovations - Stem Cell 2026 (Netherlands)
- Comparative Genomics - Genome 2026 (Singapore)
- Epidermis Stem Cell & Cancer Epidemiology - Cell Signaling 2026 (France)
- Epigenomics and Epigenetics - Genome 2026 (Singapore)
- Ethical, Legal, and Social Implications in Stem Cell Research - Stemgen 2026 (Japan)
- Ethical, Regulatory & Quality Control Frameworks - Stem Cell 2026 (Netherlands)
- Exosomes, Extracellular Vesicles & Cell-Free Therapeutics - Stem Cell 2026 (Netherlands)
- Functional Genomics - Genome 2026 (Singapore)
- Future Trends: Organoids, Bioengineering, and Next-Generation Therapies - Stemgen 2026 (Japan)
- Gene Editing and CRISPR Technologies - Stemgen 2026 (Japan)
- Gene Editing and Genetic Engineering - Genome 2026 (Singapore)
- Gene Editing, CRISPR Therapies & Regenerative Genomics - Stem Cell 2026 (Netherlands)
- Genetic Disorder - Genome 2026 (Singapore)
- Genomic Instability - Genome 2026 (Singapore)
- Genomic Medicine - Genome 2026 (Singapore)
- Human Gene Therapy - Cell Signaling 2026 (France)
- Immunotherapy - Cell Signaling 2026 (France)
- Induced Pluripotent Stem Cells (iPSCs) and Reprogramming - Stemgen 2026 (Japan)
- Mesenchymal Stem Cells (MSCs) in Therapy - Stemgen 2026 (Japan)
- Microbial Genomics - Genome 2026 (Singapore)
- Molecular Epigenetics - Cell Signaling 2026 (France)
- Nano-Therapy - Cell Signaling 2026 (France)
- Nanotechnology in Stem Cell - Cell Signaling 2026 (France)
- Next generation sequencing - Genome 2026 (Singapore)
- Nutrigenomics - Genome 2026 (Singapore)
- Personalized and Regenerative Medicine - Genome 2026 (Singapore)
- Pharmacogenomics - Genome 2026 (Singapore)
- Plant Genomics and Molecular Pharming - Genome 2026 (Singapore)
- Regeneration in Neurodegenerative & Spinal Cord Disorders - Stem Cell 2026 (Netherlands)
- Regenerative Approaches in Diabetes & Metabolic Disorders - Stem Cell 2026 (Netherlands)
- Regenerative Dentistry and Craniofacial Applications - Stemgen 2026 (Japan)
- Regenerative Immunology & Immune Modulation - Stem Cell 2026 (Netherlands)
- Regenerative Medicine - Cell Signaling 2026 (France)
- Regenerative Medicine and Tissue Engineering - Stemgen 2026 (Japan)
- Regulatory and Ethical Issues of Therapies. - Cell Signaling 2026 (France)
- Stem Cell Banking and Cryopreservation - Stemgen 2026 (Japan)
- Stem Cell Biology and Cellular Mechanisms - Stemgen 2026 (Japan)
- Stem Cell Engineering & Cellular Reprogramming - Stem Cell 2026 (Netherlands)
- Stem Cell in Drug Development - Cell Signaling 2026 (France)
- Stem Cell Therapies - Cell Signaling 2026 (France)
- Stem Cells in Neurological and Neurodegenerative Disorders - Stemgen 2026 (Japan)
- Structural Genomics - Genome 2026 (Singapore)
- Tissue Engineering, Biomaterials & Smart Scaffolds - Stem Cell 2026 (Netherlands)
- Trends in Genomics and Pharmacogenomics - Genome 2026 (Singapore)

